Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Medpace Holdings Inc (MEDP) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance

Medpace Holdings IncTrade
Vanguard Ultra Short Bond ETFTrade

Price performance (Past 24H)

Key statistics

Medpace Holdings Inc vs Vanguard Ultra Short Bond ETF — how do they compare? Medpace Holdings Inc trades at $532.89 (market cap $15.08B), while Vanguard Ultra Short Bond ETF trades at $49.71. The key difference: Medpace Holdings Inc is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.

MEDPVUSB
Market Cap
$15.08B
Sector
TechnologyLeveraged / Inverse
52-Week High
$620.59$50.03
52-Week Low
$308.88$49.60
Enterprise Value
$14.55B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Medpace Holdings Inc

MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.

MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.

Vanguard Ultra Short Bond ETF

VUSB trades at $49.70, up 0.02% on the day, with a bullish technical signal driven by positive momentum indicators. The ETF offers a yield of approximately 4.35%, positioning it as an alternative to money-market funds. Recent dividend payments include $0.18 in April 2026 and $0.17 in May 2026, with another $0.18 scheduled for July 2026.

The outlook for VUSB is supported by potential Federal Reserve rate increases enhancing short-term bond appeal, but risks include credit and duration exposure. The ETF remains a conservative income vehicle amid a non-inverted yield curve, though its technicals show mixed signals with overbought short-term RSI.

Returns comparison

Trailing returns across standard periods

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP

About Vanguard Ultra Short Bond ETF

VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.

Read more on VUSB